D.E. Shaw & Co’s Esperion Therapeutics ESPR Stock Holding History

D.E. Shaw & Co’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$520K	–	4165
2020 Q4	$520K	Hold	20,000	–	–	﹤0.01%	3368
2020 Q3	$743K	Hold	20,000	–	–	﹤0.01%	3036
2020 Q2	$1.03M	Hold	20,000	–	–	﹤0.01%	2910
2020 Q1	$631K	Sell	20,000 -9,000	-31%	-$475K	﹤0.01%	3076
2019 Q4	$1.73M	Hold	29,000	–	–	﹤0.01%	2589
2019 Q3	$1.06M	Hold	29,000	–	–	﹤0.01%	2790
2019 Q2	$1.35M	Sell	29,000 -100	-0.3%	-$4.7K	﹤0.01%	2499
2019 Q1	$1.17M	Buy	29,100 +100	+0.3%	+$4.49K	﹤0.01%	2512
2018 Q4	$1.33M	Buy	29,000 +10,000	+53%	+$482K	﹤0.01%	2460
2018 Q3	$843K	Sell	19,000 -41,200	-68%	-$1.89M	﹤0.01%	2789
2018 Q2	$2.36M	Buy	+60,200	New	+$3.04M	﹤0.01%	2107
2015 Q4	–	Sell	-10,000	Closed	-$236K	–	3847
2015 Q3	$236K	Hold	10,000	–	–	﹤0.01%	3433
2015 Q2	$818K	Buy	+10,000	New	+$979K	﹤0.01%	2843

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

D.E. Shaw & Co's ESPR Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 6,540,785 shares — an estimated $17.9M sold.

D.E. Shaw & Co first reported a position in ESPR in Q1 2015 and held it in 24 quarters. The position peaked at $25.5M in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

D.E. Shaw & Co reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 6,540,785 Esperion Therapeutics shares in Q2 2026, an estimated $17.9M.
D.E. Shaw & Co first reported a position in Esperion Therapeutics in Q1 2015 and held it in 24 quarters.
D.E. Shaw & Co's Esperion Therapeutics position peaked at $25.5M in Q4 2025.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.